{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T12:56:53Z","timestamp":1794315413328,"version":"4.9.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1038\/s41584-026-01354-w","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T12:35:20Z","timestamp":1772454920000},"page":"319-327","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Bridging the gap: combining treat-to-target and difficult-to-treat strategies in the management of rheumatoid arthritis"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5878-5232","authenticated-orcid":false,"given":"Lilla","family":"Gunkl-T\u00f3th","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4449-8501","authenticated-orcid":false,"given":"Iain B.","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1198-3228","authenticated-orcid":false,"given":"Gy\u00f6rgy","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"1354_CR1","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/ard.2009.123919","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen, J. S. et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis. 69, 631\u2013637 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"1354_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen, J. S. et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann. Rheum. Dis. 75, 3\u201315 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1354_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann. Rheum. Dis. 82, 3\u201318 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1354_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","volume":"80","author":"G Nagy","year":"2021","unstructured":"Nagy, G. et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann. Rheum. Dis. 80, 31\u201335 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"1354_CR5","unstructured":"National Human Genome Research Institute. Precision medicine https:\/\/www.genome.gov\/genetics-glossary\/Precision-Medicine (2025)."},{"key":"1354_CR6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/cts.12884","volume":"14","author":"KB Johnson","year":"2021","unstructured":"Johnson, K. B. et al. Precision medicine, AI, and the future of personalized health care. Clin. Transl. Sci. 14, 86\u201393 (2021).","journal-title":"Clin. Transl. Sci."},{"key":"1354_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","volume":"364","author":"C Grigor","year":"2004","unstructured":"Grigor, C. et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364, 263\u2013269 (2004).","journal-title":"Lancet"},{"key":"1354_CR8","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1136\/annrheumdis-2019-216819","volume":"79","author":"S Ramiro","year":"2020","unstructured":"Ramiro, S. et al. Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). Ann. Rheum. Dis. 79, 453\u2013459 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"1354_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/rheumatology\/keae544","volume":"64","author":"ZLM Hofman","year":"2024","unstructured":"Hofman, Z. L. M. et al. Difficult-to-treat rheumatoid arthritis: what have we learned and what do we still need to learn? Rheumatology 64, 65\u201373 (2024).","journal-title":"Rheumatology"},{"key":"1354_CR10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/annrheumdis-2021-220973","volume":"81","author":"G Nagy","year":"2022","unstructured":"Nagy, G. et al. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann. Rheum. Dis. 81, 20\u201333 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1354_CR11","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1093\/rheumatology\/keac584","volume":"62","author":"M Dey","year":"2023","unstructured":"Dey, M., Nagy, G. & Nikiphorou, E. Comorbidities and extra-articular manifestations in difficult-to-treat rheumatoid arthritis: different sides of the same coin? Rheumatology 62, 1773\u20131779 (2023).","journal-title":"Rheumatology"},{"key":"1354_CR12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s13075-025-03674-w","volume":"27","author":"K Fritsch","year":"2025","unstructured":"Fritsch, K. et al. Screening for rheumatoid arthritis-associated interstitial lung disease using low-dose CT: an emerging approach \u2014 an observational prospective case-control study. Arthritis Res. Ther. 27, 208 (2025).","journal-title":"Arthritis Res. Ther."},{"key":"1354_CR13","doi-asserted-by":"publisher","first-page":"1607018","DOI":"10.3389\/fcvm.2025.1607018","volume":"12","author":"Z Tarjanyi","year":"2025","unstructured":"Tarjanyi, Z. et al. Subclinical myocardial changes in rheumatoid arthritis: cardiovascular magnetic resonance evidence of immuno-inflammatory remodeling. Front. Cardiovasc. Med. 12, 1607018 (2025).","journal-title":"Front. Cardiovasc. Med."},{"key":"1354_CR14","doi-asserted-by":"publisher","first-page":"e274","DOI":"10.1016\/S2665-9913(24)00340-0","volume":"7","author":"G Nagy","year":"2025","unstructured":"Nagy, G., Gunkl-T\u00f3th, L., Dorg\u00f3, A. M. & McInnes, I. B. The concept of difficult-to-treat disease in rheumatology: where next? Lancet Rheumatol. 7, e274\u2013e289 (2025).","journal-title":"Lancet Rheumatol."},{"key":"1354_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13075-024-03432-4","volume":"27","author":"N Luciano","year":"2025","unstructured":"Luciano, N. et al. Obesity and fibromyalgia are associated with difficult-to-treat rheumatoid arthritis (D2T-RA) independent of age and gender. Arthritis Res. Ther. 27, 2 (2025).","journal-title":"Arthritis Res. Ther."},{"key":"1354_CR16","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/art.42767","volume":"76","author":"P David","year":"2024","unstructured":"David, P. et al. Poly-refractory rheumatoid arthritis: an uncommon subset of difficult to treat disease with distinct inflammatory and noninflammatory phenotypes. Arthritis Rheumatol. 76, 510\u2013521 (2024).","journal-title":"Arthritis Rheumatol."},{"key":"1354_CR17","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.autrev.2011.04.026","volume":"10","author":"C Vasconcelos","year":"2011","unstructured":"Vasconcelos, C., Kallenberg, C. & Shoenfeld, Y. Refractory disease in autoimmune diseases. Autoimmun. Rev. 10, 653\u2013654 (2011).","journal-title":"Autoimmun. Rev."},{"key":"1354_CR18","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1007\/s10067-025-07626-2","volume":"44","author":"R Garcia-Salinas","year":"2025","unstructured":"Garcia-Salinas, R. et al. Difficult-to-manage axial spondyloarthritis according to ASAS criteria in Reuma-Check cohort: frequency, predictive factors, and treatment patterns. Clin. Rheumatol. 44, 3959\u20133965 (2025).","journal-title":"Clin. Rheumatol."},{"key":"1354_CR19","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.ard.2025.01.035","volume":"84","author":"D Poddubnyy","year":"2025","unstructured":"Poddubnyy, D. et al. The assessment of spondyloarthritis international society (ASAS) consensus-based expert definition of difficult-to-manage, including treatment-refractory, axial spondyloarthritis. Ann. Rheum. Dis. 84, 538\u2013546 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1354_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41584-020-00541-7","volume":"17","author":"MH Buch","year":"2021","unstructured":"Buch, M. H., Eyre, S. & McGonagle, D. Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nat. Rev. Rheumatol. 17, 17\u201333 (2021).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1354_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2025-006271","volume":"11","author":"G Nagy","year":"2025","unstructured":"Nagy, G. & Buch, M. H. Strengths and limitations of the EULAR definition for difficult-to-treat rheumatoid arthritis. RMD Open 11, e006271 (2025).","journal-title":"RMD Open"},{"key":"1354_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103423","volume":"22","author":"P Sarzi-Puttini","year":"2023","unstructured":"Sarzi-Puttini, P., Zen, M., Arru, F., Giorgi, V. & Choy, E. A. Residual pain in rheumatoid arthritis: is it a real problem? Autoimmun. Rev. 22, 103423 (2023).","journal-title":"Autoimmun. Rev."},{"key":"1354_CR23","doi-asserted-by":"publisher","first-page":"845","DOI":"10.3389\/fimmu.2020.00845","volume":"11","author":"A Nerviani","year":"2020","unstructured":"Nerviani, A. et al. A pauci-immune synovial pathotype predicts inadequate response to TNF\u03b1-blockade in rheumatoid arthritis patients. Front. Immunol. 11, 845 (2020).","journal-title":"Front. Immunol."},{"key":"1354_CR24","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/art.40428","volume":"70","author":"DE Orange","year":"2018","unstructured":"Orange, D. E. et al. Identification of three rheumatoid arthritis disease subtypes by machine learning integration of synovial histologic features and RNA sequencing data. Arthritis Rheumatol. 70, 690\u2013701 (2018).","journal-title":"Arthritis Rheumatol."},{"issue":"Suppl.","key":"1354_CR25","doi-asserted-by":"publisher","first-page":"152588","DOI":"10.1016\/j.semarthrit.2024.152588","volume":"70","author":"MH Smith","year":"2025","unstructured":"Smith, M. H. et al. Characterizing molecular targets in difficult-to-treat rheumatoid arthritis. Semin. Arthritis Rheum. 70 (Suppl.), 152588 (2025).","journal-title":"Semin. Arthritis Rheum."},{"key":"1354_CR26","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41586-023-06708-y","volume":"623","author":"F Zhang","year":"2023","unstructured":"Zhang, F. et al. Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes. Nature 623, 616\u2013624 (2023).","journal-title":"Nature"},{"key":"1354_CR27","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1136\/annrheumdis-2018-214539","volume":"78","author":"F Humby","year":"2019","unstructured":"Humby, F. et al. Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. Ann. Rheum. Dis. 78, 761\u2013772 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1354_CR28","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1136\/annrheumdis-2019-215751","volume":"78","author":"G Lliso-Ribera","year":"2019","unstructured":"Lliso-Ribera, G. et al. Synovial tissue signatures enhance clinical classification and prognostic\/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the Pathobiology of Early Arthritis Cohort (PEAC). Ann. Rheum. Dis. 78, 1642\u20131652 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1354_CR29","doi-asserted-by":"publisher","first-page":"eadk3506","DOI":"10.1126\/scitranslmed.adk3506","volume":"16","author":"Z Bai","year":"2024","unstructured":"Bai, Z. et al. Synovial fibroblast gene expression is associated with sensory nerve growth and pain in rheumatoid arthritis. Sci. Transl. Med. 16, eadk3506 (2024).","journal-title":"Sci. Transl. Med."},{"key":"1354_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04648-0","volume":"9","author":"A Schrepf","year":"2018","unstructured":"Schrepf, A. et al. A multi-modal MRI study of the central response to inflammation in rheumatoid arthritis. Nat. Commun. 9, 2243 (2018).","journal-title":"Nat. Commun."},{"key":"1354_CR31","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/art.40451","volume":"70","author":"N Basu","year":"2018","unstructured":"Basu, N. et al. Neurobiologic features of fibromyalgia are also present among rheumatoid arthritis patients. Arthritis Rheumatol. 70, 1000\u20131007 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"1354_CR32","volume":"16","author":"H El-Kasmi","year":"2024","unstructured":"El-Kasmi, H. et al. The prevalence of fibromyalgia in rheumatoid arthritis patients using the fibromyalgia assessment screening tool (FAST 4) based on the multidimensional health assessment questionnaire (MDHAQ). Cureus 16, e64011 (2024).","journal-title":"Cureus"},{"key":"1354_CR33","doi-asserted-by":"publisher","first-page":"9724371","DOI":"10.1155\/2017\/9724371","volume":"2017","author":"J Sheng","year":"2017","unstructured":"Sheng, J., Liu, S., Wang, Y., Cui, R. & Zhang, X. The link between depression and chronic pain: neural mechanisms in the brain. Neural Plast. 2017, 9724371 (2017).","journal-title":"Neural Plast."},{"key":"1354_CR34","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1136\/ard.49.11.916","volume":"49","author":"DM van der Heijde","year":"1990","unstructured":"van der Heijde, D. M. et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann. Rheum. Dis. 49, 916\u2013920 (1990).","journal-title":"Ann. Rheum. Dis."},{"key":"1354_CR35","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","volume":"42","author":"JS Smolen","year":"2003","unstructured":"Smolen, J. S. et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 42, 244\u2013257 (2003).","journal-title":"Rheumatology"},{"key":"1354_CR36","doi-asserted-by":"publisher","first-page":"R796","DOI":"10.1186\/ar1740","volume":"7","author":"D Aletaha","year":"2005","unstructured":"Aletaha, D. et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res. Ther. 7, R796\u2013R806 (2005).","journal-title":"Arthritis Res. Ther."},{"key":"1354_CR37","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1136\/annrheumdis-2012-203158","volume":"72","author":"AN Colebatch","year":"2013","unstructured":"Colebatch, A. N. et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann. Rheum. Dis. 72, 804\u2013814 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"1354_CR38","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fmed.2018.00040","volume":"5","author":"H Canh\u00e3o","year":"2018","unstructured":"Canh\u00e3o, H. et al. Common evaluations of disease activity in rheumatoid arthritis each discordant classifications across different populations. Front. Med. 5, 40 (2018).","journal-title":"Front. Med."},{"key":"1354_CR39","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/acr.24336","volume":"72","author":"TM Johnson","year":"2020","unstructured":"Johnson, T. M., Michaud, K. & England, B. R. Measures of rheumatoid arthritis disease activity. Arthritis Care Res. 72, 4\u201326 (2020).","journal-title":"Arthritis Care Res."},{"key":"1354_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0273789","volume":"17","author":"IA Santos","year":"2022","unstructured":"Santos, I. A. et al. Comparison of rheumatoid arthritis composite disease activity indices and residual activity in a Brazilian multicenter study- REAL study. PLoS ONE 17, e0273789 (2022).","journal-title":"PLoS ONE"},{"key":"1354_CR41","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s41927-018-0016-9","volume":"2","author":"DF McWilliams","year":"2018","unstructured":"McWilliams, D. F. et al. Interpretation of DAS28 and its components in the assessment of inflammatory and non-inflammatory aspects of rheumatoid arthritis. BMC Rheumatol. 2, 8 (2018).","journal-title":"BMC Rheumatol."},{"key":"1354_CR42","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1093\/rheumatology\/keaf179","volume":"64","author":"T Pincus","year":"2025","unstructured":"Pincus, T., Li, T. & Gibson, K. A. Elevated DAS28, CDAI, RAPID3 and five of seven RA core data set measures in patients with positive screens for anxiety, depression or fibromyalgia on an MDHAQ. Rheumatology 64, 4555\u20134564 (2025).","journal-title":"Rheumatology"},{"key":"1354_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-019-2773-z","volume":"20","author":"SW Lee","year":"2019","unstructured":"Lee, S. W., Kim, S. Y. & Chang, S. H. Prevalence of feet and ankle arthritis and their impact on clinical indices in patients with rheumatoid arthritis: a cross-sectional study. BMC Musculoskelet. Disord. 20, 420 (2019).","journal-title":"BMC Musculoskelet. Disord."},{"key":"1354_CR44","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/acr2.11258","volume":"3","author":"MB Simonsen","year":"2021","unstructured":"Simonsen, M. B., H\u00f8rslev-Petersen, K., C\u00f6ster, M. C., Jensen, C. & Bremander, A. Foot and ankle problems in patients with rheumatoid arthritis in 2019: still an important issue. ACR Open Rheumatol. 3, 396\u2013402 (2021).","journal-title":"ACR Open Rheumatol."},{"key":"1354_CR45","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1136\/annrheumdis-2015-208941","volume":"75","author":"J Dale","year":"2016","unstructured":"Dale, J. et al. Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial. Ann. Rheum. Dis. 75, 1043\u20131050 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1354_CR46","doi-asserted-by":"publisher","first-page":"i4205","DOI":"10.1136\/bmj.i4205","volume":"354","author":"EA Haavardsholm","year":"2016","unstructured":"Haavardsholm, E. A. et al. Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial. BMJ 354, i4205 (2016).","journal-title":"BMJ"},{"key":"1354_CR47","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1001\/jama.2018.21362","volume":"321","author":"S M\u00f8ller-Bisgaard","year":"2019","unstructured":"M\u00f8ller-Bisgaard, S. et al. Effect of magnetic resonance imaging vs conventional treat-to-target strategies on disease activity remission and radiographic progression in rheumatoid arthritis: the IMAGINE-RA randomized clinical trial. JAMA 321, 461\u2013472 (2019).","journal-title":"JAMA"},{"key":"1354_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002796","volume":"8","author":"L Terslev","year":"2022","unstructured":"Terslev, L. et al. Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors. RMD Open 8, e002796 (2022).","journal-title":"RMD Open"},{"key":"1354_CR49","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s40477-024-00963-z","volume":"28","author":"G A\u00f1ez","year":"2025","unstructured":"A\u00f1ez, G. et al. Clinical and ultrasound optimization in rheumatoid arthritis for patients in sustained remission, can it work as a new optimization tool? J. Ultrasound 28, 81\u201387 (2025).","journal-title":"J. Ultrasound"},{"key":"1354_CR50","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1093\/rheumatology\/keac114","volume":"61","author":"NMT Roodenrijs","year":"2022","unstructured":"Roodenrijs, N. M. T. et al. Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search. Rheumatology 61, 3552\u20133566 (2022).","journal-title":"Rheumatology"},{"key":"1354_CR51","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41584-022-00845-w","volume":"18","author":"CMA Lin","year":"2022","unstructured":"Lin, C. M. A., Cooles, F. A. H. & Isaacs, J. D. Precision medicine: the precision gap in rheumatic disease. Nat. Rev. Rheumatol. 18, 725\u2013733 (2022).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1354_CR52","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.autrev.2018.06.001","volume":"17","author":"D McGonagle","year":"2018","unstructured":"McGonagle, D., Watad, A. & Savic, S. Mechanistic immunological based classification of rheumatoid arthritis. Autoimmun. Rev. 17, 1115\u20131123 (2018).","journal-title":"Autoimmun. Rev."},{"key":"1354_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2025.102106","volume":"39","author":"T Gudu","year":"2025","unstructured":"Gudu, T., Oztas, M. & Nikiphorou, E. Contemporary approaches to the management of rheumatoid arthritis: precision and progress. Best. Pract. Res. Clin. Rheumatol. 39, 102106 (2025).","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"1354_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152740","volume":"73","author":"J Avouac","year":"2025","unstructured":"Avouac, J., Kay, J. & Choy, E. Personalised treatment of rheumatoid arthritis based on cytokine profiles and synovial tissue signatures: potentials and challenges. Semin. Arthritis Rheum. 73, 152740 (2025).","journal-title":"Semin. Arthritis Rheum."},{"key":"1354_CR55","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1093\/rheumatology\/kev421","volume":"55","author":"BV Cuppen","year":"2016","unstructured":"Cuppen, B. V. et al. Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability. Rheumatology 55, 826\u2013839 (2016).","journal-title":"Rheumatology"},{"key":"1354_CR56","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/art.39946","volume":"69","author":"L Tweehuysen","year":"2017","unstructured":"Tweehuysen, L. et al. Little evidence for usefulness of biomarkers for predicting successful dose reduction or discontinuation of a biologic agent in rheumatoid arthritis: a systematic review. Arthritis Rheumatol. 69, 301\u2013308 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"1354_CR57","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002570","volume":"8","author":"MHM Wientjes","year":"2022","unstructured":"Wientjes, M. H. M., den Broeder, A. A., Welsing, P. M. J., Verhoef, L. M. & van den Bemt, B. J. F. Prediction of response to anti-TNF treatment using laboratory biomarkers in patients with rheumatoid arthritis: a systematic review. RMD Open 8, e002570\u00a0(2022).","journal-title":"RMD Open"},{"key":"1354_CR58","doi-asserted-by":"publisher","first-page":"102021","DOI":"10.1016\/j.berh.2024.102021","volume":"39","author":"M Neto","year":"2025","unstructured":"Neto, M., Mendes, B., Albuquerque, F. & da Silva, J. A. P. Novel biomarkers in RA: implication for diagnosis, prognosis, and personalised treatment. Best Pract. Res. Clin. Rheumatol. 39, 102021 (2025).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"1354_CR59","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13075-021-02567-y","volume":"23","author":"BS Koo","year":"2021","unstructured":"Koo, B. S. et al. Machine learning model for identifying important clinical features for predicting remission in patients with rheumatoid arthritis treated with biologics. Arthritis Res. Ther. 23, 178 (2021).","journal-title":"Arthritis Res. Ther."},{"key":"1354_CR60","doi-asserted-by":"publisher","first-page":"1526708","DOI":"10.3389\/fmed.2025.1526708","volume":"12","author":"G Li","year":"2025","unstructured":"Li, G. et al. Development of machine learning models for predicting non-remission in early RA highlights the robust predictive importance of the RAID score-evidence from the ARCTIC study. Front. Med. 12, 1526708 (2025).","journal-title":"Front. Med."},{"key":"1354_CR61","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.0606","volume":"2","author":"B Norgeot","year":"2019","unstructured":"Norgeot, B. et al. Assessment of a deep learning model based on electronic health record data to forecast clinical outcomes in patients with rheumatoid arthritis. JAMA Netw. Open 2, e190606 (2019).","journal-title":"JAMA Netw. Open"},{"key":"1354_CR62","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00296-025-05825-3","volume":"45","author":"D Benavent","year":"2025","unstructured":"Benavent, D. et al. Artificial intelligence to predict treatment response in rheumatoid arthritis and spondyloarthritis: a scoping review. Rheumatol. Int. 45, 91 (2025).","journal-title":"Rheumatol. Int."},{"key":"1354_CR63","doi-asserted-by":"publisher","first-page":"1409555","DOI":"10.3389\/fimmu.2024.1409555","volume":"15","author":"Y Shi","year":"2024","unstructured":"Shi, Y. et al. Advancing precision rheumatology: applications of machine learning for rheumatoid arthritis management. Front. Immunol. 15, 1409555\u00a0(2024).","journal-title":"Front. Immunol."},{"key":"1354_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-18298-y","volume":"15","author":"J Baloun","year":"2025","unstructured":"Baloun, J. et al. Machine learning-assisted screening of clinical features for predicting difficult-to-treat rheumatoid arthritis. Sci. Rep. 15, 34747 (2025).","journal-title":"Sci. Rep."},{"key":"1354_CR65","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/acr.25654","volume":"78","author":"ML Paudel","year":"2026","unstructured":"Paudel, M. L. et al. Development and external validation of a multivariable predictive model for progression to difficult-to-treat rheumatoid arthritis in biologic-experienced patients. Arthritis Care Res. 78, 54\u201365 (2026).","journal-title":"Arthritis Care Res."},{"key":"1354_CR66","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1093\/rheumatology\/keae265","volume":"63","author":"R Watanabe","year":"2024","unstructured":"Watanabe, R. et al. Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: the ANSWER cohort study. Rheumatology 63, 2418\u20132426 (2024).","journal-title":"Rheumatology"},{"key":"1354_CR67","doi-asserted-by":"publisher","first-page":"136","DOI":"10.2471\/BLT.24.292168","volume":"103","author":"A Santosa","year":"2025","unstructured":"Santosa, A., Li, J. W. & Tan, T. C. Randomized controlled trials of digital health interventions for rheumatic disease management: a systematic review. Bull. World Health Organ. 103, 136\u2013147 (2025).","journal-title":"Bull. World Health Organ."},{"key":"1354_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152045","volume":"56","author":"LE Jackson","year":"2022","unstructured":"Jackson, L. E. et al. Telemedicine in rheumatology care: a systematic review. Semin. Arthritis Rheum. 56, 152045 (2022).","journal-title":"Semin. Arthritis Rheum."},{"key":"1354_CR69","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkac021","volume":"6","author":"J Gandrup","year":"2022","unstructured":"Gandrup, J., Selby, D. A., van der Veer, S. N., McBeth, J. & Dixon, W. G. Using patient-reported data from a smartphone app to capture and characterize real-time patient-reported flares in rheumatoid arthritis. Rheumatol. Adv. Pract. 6, rkac021 (2022).","journal-title":"Rheumatol. Adv. Pract."},{"key":"1354_CR70","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1093\/rheumatology\/keaa462","volume":"60","author":"Y-M Pers","year":"2020","unstructured":"Pers, Y.-M. et al. A randomized prospective open-label controlled trial comparing the performance of a connected monitoring interface versus physical routine monitoring in patients with rheumatoid arthritis. Rheumatology 60, 1659\u20131668 (2020).","journal-title":"Rheumatology"},{"key":"1354_CR71","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.csbj.2022.11.050","volume":"21","author":"E Athieniti","year":"2023","unstructured":"Athieniti, E. & Spyrou, G. M. A guide to multi-omics data collection and integration for translational medicine. Comput. Struct. Biotechnol. J. 21, 134\u2013149 (2023).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"1354_CR72","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/annrheumdis-2015-207526","volume":"75","author":"MA Stoffer","year":"2016","unstructured":"Stoffer, M. A. et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann. Rheum. Dis. 75, 16\u201322 (2016).","journal-title":"Ann. Rheum. Dis."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01354-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01354-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01354-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:03:23Z","timestamp":1777334603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01354-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":72,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1354"],"URL":"https:\/\/doi.org\/10.1038\/s41584-026-01354-w","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"23 January 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.G.-T. has received honoraria or payment for lectures from AbbVie. I.B.M. has grants or contracts from Bristol Myers Squibb (BMS), Eli Lilly, AstraZeneca and Novartis; has received consulting fees from AbbVie, Amgen, AstraZeneca, BMS, Causeway Therapeutics, Cabaletta, Eli Lilly, Gilead, Janssen, Novartis, UCB, Pfizer, Sanofi Regeneron, Evelo, Compugen and Moonlake; has stock or stock options in Compugen and Cabaletta; is a trustee for Versus Arthritis, a board member for NHS Greater Glasgow & Clyde Health Board and the Vice Principal and Head of College at the University of Glasow. G.N. has received consulting fees from Miltenyi, AstraZeneca and Richter; has been given honoraria for lectures from AbbVie, Eli Lilly, Merck Sharp & Dohme, Swedish Orphan Biovitrum, GSK, Pfizer, Swixx, Amgen, UCB, Janssen, AstraZeneca and Takeda; has received support for attending conferences from Biotest; and is a European Alliance of Associations for Rheumatology congress committee member.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}